Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, CorMedix Inc’s stock clocked out at $12.8, down -6.57% from its previous closing price of $13.7. In other words, the price has decreased by -$6.57 from its previous closing price. On the day, 4.85 million shares were traded. CRMD stock price reached its highest trading level at $13.93 during the session, while it also had its lowest trading level at $12.76.
Ratios:
To gain a deeper understanding of CRMD’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.01 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 31.42. For the most recent quarter (mrq), Quick Ratio is recorded 7.52 and its Current Ratio is at 7.82. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 30, 2025, initiated with a Buy rating and assigned the stock a target price of $20.
On March 07, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $18.Leerink Partners initiated its Outperform rating on March 07, 2025, with a $18 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 03 ’25 when David Matthew T bought 300,000 shares for $14.50 per share.
Mistry Erin bought 1,500 shares of CRMD for $14,985 on Oct 31 ’24. The EVP, Chief Commercial Officer now owns 52,011 shares after completing the transaction at $9.99 per share. On Nov 14 ’24, another insider, Hurlburt Elizabeth, who serves as the EVP of the company, sold 140,027 shares for $11.18 each. As a result, the insider received 1,565,670 and left with 45,397 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRMD now has a Market Capitalization of 1021571904 and an Enterprise Value of 765230592. As of this moment, CorMedix’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.14, and their Forward P/E ratio for the next fiscal year is 5.51. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.87 while its Price-to-Book (P/B) ratio in mrq is 4.33. Its current Enterprise Value per Revenue stands at 6.299 whereas that against EBITDA is 15.35.
Stock Price History:
The Beta on a monthly basis for CRMD is 1.92, which has changed by 1.2222223 over the last 52 weeks, in comparison to a change of 0.20221436 over the same period for the S&P500. Over the past 52 weeks, CRMD has reached a high of $17.43, while it has fallen to a 52-week low of $5.31. The 50-Day Moving Average of the stock is 4.33%, while the 200-Day Moving Average is calculated to be 18.30%.
Shares Statistics:
It appears that CRMD traded 3.07M shares on average per day over the past three months and 5758490 shares per day over the past ten days. A total of 74.62M shares are outstanding, with a floating share count of 66.88M. Insiders hold about 10.40% of the company’s shares, while institutions hold 46.11% stake in the company. Shares short for CRMD as of 1755216000 were 14179171 with a Short Ratio of 4.61, compared to 1752537600 on 10049276. Therefore, it implies a Short% of Shares Outstanding of 14179171 and a Short% of Float of 19.189999999999998.
Earnings Estimates
Current recommendations for the stock of the company come from 5.0 analysts. The consensus estimate for the next quarter is $0.66, with high estimates of $0.86 and low estimates of $0.38.
Analysts are recommending an EPS of between $2.07 and $1.31 for the fiscal current year, implying an average EPS of $1.67. EPS for the following year is $2.38, with 5.0 analysts recommending between $3.24 and $1.72.
Revenue Estimates
In the current quarter, 5 analysts expect revenue to total $63.27M. It ranges from a high estimate of $65.24M to a low estimate of $59.4M. As of the current estimate, CorMedix Inc’s year-ago sales were $11.46MFor the next quarter, 5 analysts are estimating revenue of $98.41M. There is a high estimate of $111.6M for the next quarter, whereas the lowest estimate is $65M.
A total of 5 analysts have provided revenue estimates for CRMD’s current fiscal year. The highest revenue estimate was $255.4M, while the lowest revenue estimate was $205.82M, resulting in an average revenue estimate of $240.49M. In the same quarter a year ago, actual revenue was $43.47MBased on 5 analysts’ estimates, the company’s revenue will be $392.48M in the next fiscal year. The high estimate is $487.26M and the low estimate is $303.19M.
